<DOC>
	<DOCNO>NCT00358657</DOCNO>
	<brief_summary>This phase I/II trial study side effect fludarabine phosphate , cyclophosphamide total-body irradiation follow donor bone marrow transplant cyclophosphamide , mycophenolate mofetil , tacrolimus , sirolimus treat patient primary immunodeficiency disorder noncancerous inherited disorder . Giving low dos chemotherapy total-body irradiation bone marrow transplant help prepare patient 's body accept incoming donor 's bone marrow decrease risk patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell call graft versus host disease . Giving cyclophosphamide , mycophenolate mofetil , tacrolimus , sirolimus transplant may help decrease happen .</brief_summary>
	<brief_title>Fludarabine Phosphate , Cyclophosphamide , Total-Body Irradiation Followed Donor Bone Marrow Transplant Cyclophosphamide , Mycophenolate Mofetil , Tacrolimus , Sirolimus Treating Patients With Primary Immunodeficiency Disorders Noncancerous Inherited Disorders</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine safety nonmyeloablative conditioning hematopoietic cell transplantation ( HCT ) human leukocyte antigen ( HLA ) -haploidentical related donor patient nonmalignant inherited disorder HLA-matched relate unrelated donor . SECONDARY OBJECTIVES : I . Determine whether nonmyeloablative conditioning HCT HLA-haploidentical related donor graft establish mixed chimerism ( &gt; 5 % cluster differentiation [ CD ] 3+ donor T-cell chimerism ) patient nonmalignant inherited disorder . II . Transplant related mortality day 100 . III . Incidence severity graft-versus-host disease ( GHVD ) . IV . Immune reconstitution . V. Infections first 200 day HCT . OUTLINE : NONMYELOABLATIVE CONDITIONING REGIMEN : Patients receive fludarabine phosphate intravenously ( IV ) 1 hour day -6 -2 ; cyclophosphamide IV 1 hour day -6 -5 ; undergo total body irradiation day -1 . TRANSPLANTATION : Patients undergo allogeneic bone marrow transplant day 0 . POST-TRANSPLANT IMMUNOSUPPRESSION : Patients receive cyclophosphamide IV 1 hour day 3 4 , mycophenolate mofetil orally ( PO ) every 8 hour day 5-30 twice daily ( BID ) day 40 , evidence active GVHD donor engraftment &gt; 95 % ( Principal Investigator [ PI ] approval ) taper approximately day 96 , fast discretion PI . Patients also receive tacrolimus IV continuously 22-24 hour start day 5 post-transplant continue tacrolimus day 100 follow taper approximately day 180 evidence GVHD graft well . Patients may convert oral tacrolimus give BID three time daily ( TID ) patient able take medication orally therapeutic drug level . In addition , patient receive sirolimus orally begin day 5 day 180 follow taper approximately day 210 evidence GVHD graft well . After completion study treatment , patient follow 6 , 12 , 18 , 24 month , annually thereafter .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Primary immunodeficiency disorder nonmalignant inherit disease ( except Fanconi anemia ) treatable allogeneic HCT Patients preexist medical condition factor render high risk regimen relate toxicity ineligible conventional myeloablative HCT HLAmatched relate unrelated donor Patients related donor identical one HLA haplotype Acquired aplastic anemia : severe aplastic anemia ( SAA ) define follow : Bone marrow cellularity &lt; 25 % , marrow cellularity &lt; 50 % &lt; 30 % residual hematopoietic cell Two three follow ( peripheral blood ) : neutrophil &lt; 0.5 x 10^9/L ; platelet &lt; 20 x 10^9/L ; reticulocyte &lt; 20 x 10^9/L SAA diagnostic criterion may apply assessment initial diagnosis followup assessment DONOR : Related donor identical one HLA haplotype DONOR : Bone marrow allow stem cell source Fanconi anemia Suitably HLAmatched relate unrelated donor Patients metabolic storage disease severe central nervous system ( CNS ) involvement disease , define intelligence quotient ( IQ ) score &lt; 70 Cardiac ejection fraction &lt; 30 % ( , unable obtain ejection fraction , shorten fraction &lt; 26 % ) multiplegated acquisition ( MUGA ) scan cardiac echocardiogram ( echo ) , symptomatic coronary artery disease , cardiac failure require therapy ; patient history , current cardiac disease evaluate appropriate cardiac study and/or cardiology consult ; patient shorten fraction &lt; 26 % must see cardiology approval Poorly control hypertension despite antihypertensive medication Patients clinical laboratory evidence liver disease need evaluate cause liver disease , clinical severity term liver function degree portal hypertension ; patient exclude find fulminant liver failure , cirrhosis liver evidence portal hypertension , bridge fibrosis , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evidence prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dl , symptomatic biliary disease Positive human immunodeficiency virus ( HIV ) Females pregnant ( betahuman chorionic gonadotropin positive [ betaHCG+ ] ) breastfeed Fertile men woman unwilling use contraceptive HCT 12 month posttreatment Patients fungal pneumonia radiological progression receipt amphotericin formulation moldactive azoles great 1 month eligible protocol DONOR : Donorrecipient pair HLAmismatch hostversusgraft ( HVG ) direction ; patient homozygous donor heterozygous DONOR : Donors expect meet minimum target dose marrow cell ( 1 x 10^8 nucleated cells/kg recipient Ideal Body Weight ) DONOR : HIVpositive donor DONOR : A positive antidonor cytotoxic cross match absolute donor exclusion DONOR : &lt; 6 month old &gt; 75 year old</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>